Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Clinical trial NCT05726370 · RECRUITING

Trial details

NCT number: NCT05726370
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Head and Neck Cancer Resectable Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Second Primary Squamous Cell Carcinoma of the Head and Neck

Start date: 2023-05-20
Primary completion: 2027-12-31
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.